In 1929, Henrik Dam of Denmark discovered an "anti-hemorrhagic factor” which came to be named vitamin K, from the German/Danish word koagulationsvitamin (clotting vitamin). We know that vitamin K presents in multiple varieties but most health professionals have only been taught about vitamin K1 (phytomenadione).
In today’s episode, Dr Hogne Vik takes us through the many forms of vitamin K, their differing actions and the exciting clinical applications of vitamin K2 (menaquinone) MK-7. Discussing everything from the headline actions of vitamin K2 MK-7 in the "calcium paradox" to the benefits for menopausal women and the future exciting research in the area of immune activation.
Dr Hogne Vik serves as the Chief Medical Officer with NattoPharma ASA. A physician by education, he has a long and successful track record in both the pharmaceutical and dietary supplement industries. Prior to joining NattoPharma, Dr. Vik was the driving force behind the documentation program securing the current marketing position of Superba Krill Oil developed and manufactured by Aker BioMarine Antarctic. He was one of the key executives in the management team of Pronova BioPharma securing the US and Japanese market entrances of Omacor/Lovaza, and was instrumental in bringing Tonalin (CLA) to the European and US markets as part of Natural ASA. Additionally, as Global Vice President of Product Development with Nycomed, Dr. Vik was one of the main forces behind the development and market entrance of VisiPaque.